Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer

In Vivo. 2021 Jul-Aug;35(4):2247-2251. doi: 10.21873/invivo.12497.

Abstract

Background: Multimodality treatment including immune check point inhibitors is required for stage IV oesophagogastric junction cancer (OGJC).

Case report: A 69-year-old man, was diagnosed with advanced OGJC and para-aortic lymph node metastasis (T3N+M1, stage IV), which upon biopsy, was shown to be an adenocarcinoma. After eight courses of nivolumab as third-line chemotherapy, the primary tumour and enlarged regional and para-aortic lymph nodes shrunk markedly, while tumour markers decreased within normal ranges. We performed a minimally invasive Ivor-Lewis oesophagectomy with completion of an abdominal D2 and transhiatal lower mediastinal lymph node dissection. Pathological findings revealed a complete response for the primary tumour and a regional lymph node metastasis. A biopsy of the previous sample revealed microsatellite instability-negativity, Epstein-Barr virus-negativity, and programmed cell death-1-ligand combined positive score of 2. He was followed up for 3 months without recurrence.

Conclusion: Nivolumab may induce pathological complete response for stage IV OGJC even in cases negative for microsatellite instability and Epstein-Barr virus, besides the programmed cell death-1-ligand combined positive score of <5.

Keywords: Conversion surgery; Epstein-Barr virus; microsatellite instability; nivolumab; oesophagogastric junction cancer; programmed cell death-1-ligand.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Epstein-Barr Virus Infections*
  • Esophagectomy
  • Esophagogastric Junction / surgery
  • Herpesvirus 4, Human
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Male
  • Neoplasm Recurrence, Local
  • Nivolumab / therapeutic use
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / surgery

Substances

  • Nivolumab